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Objectives:
 
 Treatments for acromegaly, a growth hor-
mone disorder, can be burdensome to patients, often re-
quiring multiple self-administered injections daily. We
developed the Impact on Lifestyle Questionnaire (ILQ)
to measure the impact on patient’s lifestyle imposed by
the burden of injectable treatments for acromegaly. The
primary objective of this study was to establish the reli-
ability and validity of the ILQ.
 
Methods:
 
 The ILQ consists of the SF-12 and 30 addi-
tional questions. Thirty-four patients, from two sites,
completed the ILQ and scales measuring related con-
cepts. Fourteen patients also completed a retest survey 4
weeks later. Survey sample data were combined with
ILQ data from another 56 patients with acromegaly for
a factor analysis. Reliability was assessed with Cron-
 
bach’s 
 

 
 and test-retest. Zero-order correlations were
examined between ILQ subscales and symptoms, de-
pression, SF-12 mental and physical components, a mea-
sure of self-care burden, appraisal of illness, and single-
item measures of quality of life and satisfaction.
 
Results:
 
 The preconceived subscale structure was sup-
ported by factor analysis. These factors were internally
consistent and stable over time. Good convergent validity
was demonstrated between the Burden and Disruption
scales with other measures of the burden of treatment. Pa-
tients indicated that they were generally compliant with
therapy, and that treatment was not particularly burden-
some or disruptive. Results based on the ILQ were consis-
tent with other scales and qualitative responses.
 
Conclusions:
 
 The ILQ has three subscales, Burden, Life-
style Disruption, and Compliance, that are reliable and
demonstrate preliminary evidence of construct validity.
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: acromegaly, impact on lifestyle, quality of
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Introduction
 
Acromegaly is a rare endocrine disorder, first de-
scribed by Marie in 1886, and first identified as a
potential pituitary disorder in 1909 [1]. The clini-
cal features of acromegaly are caused by excessive
secretion of growth hormone and its target hor-
mone, insulin-like growth factor-I (IGF-I), typi-
cally resulting from a pituitary adenoma. These
may include coarsening of facial features, excessive
sweating, amenorrhea, impotence, diabetes melli-
tus, headache, and sleep apnea, among others. Left
untreated, acromegaly may result in severe conse-
quences such as disabling arthritis, visual impair-
ment, hypertension, cardiomyopathy, diabetes melli-
tus, sleep apnea, and pituitary failure, as well as
an increased risk of gastrointestinal cancer [2–6].
Acromegaly is thought to occur at an annual inci-
dence rate of 0.0003%, with a prevalence of 40–60
per million (0.004%–0.006%) [7].
The goal of treatment is to induce a remission
of the hypersomatotropic state and to alleviate the
compressive effects of the pituitary tumor [1]. Sur-
gery is often the first line of treatment, but surgical
success is highly correlated with the experience of
the surgeon as well as the characteristics of the tu-
mor. One study found a 74% success rate in 1360
cases worldwide, using a modest criterion for suc-
 
cess (growth hormone 
 

 
10 
 

 
g/l), with significant
complications such as leakage of cerebrospinal
fluid occurring in 5% of patients [8]. Another
study found a 57% overall cure rate for surgery in
162 patients undergoing transsphenoidal surgery
over an 18-year period [9]. As a result, many pa-
tients require additional drug therapy to control
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their symptoms and prevent long-term complica-
tions. Radiation is typically used if surgery or phar-
macotherapy have failed to control the disease [1].
A variety of drug therapies are available, including
dopamine agonists such as bromocriptine, and so-
matostatin analogues such as octreotide [1]. Al-
though these agents can produce rapid relief of
symptoms, once growth hormone levels start to
rise, the symptoms may return. As a result, these
agents must be administered subcutaneously up to
4 times per day, resulting in a potentially substan-
tial impact of treatment on lifestyle.
Recently, a long-acting form of octreotide has
been developed, one that only requires injection
every 30 days. This formulation has the potential
to reduce the treatment burden for patients who
are taking octreotide injections 3 or 4 times a day.
Both the subcutaneous and long-acting formula-
tions of octreotide are marketed by Novartis Phar-
maceuticals Corporation (East Hanover, NJ).
A conceptual model of the impact of treatments
for acromegaly on patient lifestyle was developed
prior to the development of the specific items in
the Impact on Lifestyle Questionnaire (ILQ). In
this conceptualization, any therapy for acrome-
galy imposes a burden on the patient, due to the
worry and inconvenience associated with treat-
ments that require self-injection. This burden re-
sults in a disruption of lifestyle to the extent to
which treatment disrupts role and social function-
ing and leisure activities. Both the burden of treat-
ment and the disruption it causes should reduce
compliance, treatment satisfaction, and quality of
life. The purpose of the current study was to es-
tablish the reliability and validity of a new ques-
tionnaire developed to measure the impact of ther-
apies for acromegaly on patients as conceived by
this model.
Additional measures were included in the
study. These included a measure of symptom dis-
tress to assess the current burden of disease, a
measure of appraisal of illness to assess the per-
ceived stress associated with acromegaly, a mea-
sure of the burden of self-care, and a measure of
depression (see Methods section for description of
the specific measures used). We anticipated that
the ILQ would be strongly associated with the
other measure of self-care burden, as they were
both measuring similar constructs, although using
different underlying conceptual models. Depres-
sion was included because it occurs commonly in
acromegaly and is associated with both reduced
functioning and reduced compliance; we wanted
to examine whether the impact on lifestyle we
 
measured could be accounted for by depression
alone or whether the burden and disruption asso-
ciated with treatment also contributed to its im-
pact.
 
Methods
 
Participants
 
Participants were patients diagnosed with acrome-
galy, currently over 18 years old and receiving treat-
ment with the subcutaneous formulation of oct-
reotide. Patients were recruited at two clinical sites
in the United States and diagnoses were confirmed
via chart review.
 
Procedure
 
Once potential patients were identified at each
site, they were sent a letter from their physician
and a survey questionnaire. Participants were in-
structed to complete the questionnaire and return
the survey to their physician in an enclosed enve-
lope. At one site, participants were asked to sign
an informed consent form and return that with the
questionnaire; the Institutional Review Board at
the other site felt that return of the questionnaire
would indicate the patient’s consent and did not
require a separate form. A total of 55 eligible pa-
tients were identified and received surveys, and 39
patients returned the survey (response rate of
70.9%). Five of these patients did not complete
the ILQ and were removed from the subsequent
analyses. No information was available about the
reasons patients did not return the surveys. Ac-
cordingly, the overall valid response rate was
61.8%.
At one site, all 26 patients who returned their
survey were sent a second brief questionnaire in-
cluding the ILQ for the purpose of testing its test-
retest reliability. Fourteen patients (53.8%) re-
turned the second survey.
In addition, we used the baseline data on the
ILQ from 56 patients with acromegaly who were
participating in a concurrent clinical trial in order
to gain statistical power for a factor analysis. These
individuals met the criteria for the survey: namely,
they were over 18 years of age, they had a diagno-
sis of acromegaly, and they were using the subcu-
taneous formulation of octreotide (at baseline).
 
Survey Instrument
 
Demographic information.
 
Baseline patient char-
acteristics including age, race, sex, education, and
marital status were collected.
 Validating the ILQ
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Acromegaly History and Treatment History.
 
A
series of questions assessed duration of acromeg-
aly symptoms, treatment history, length of time on
octreotide, use of other medications, concurrent
illnesses, and other pertinent information about
the patient’s medical history.
 
Impact on Lifestyle Questionnaire.
 
The ILQ con-
sisted of the SF-12 [10] and 30 additional ques-
tions designed to capture the impact of octreotide
on patient’s lifestyles. The ILQ questions were ini-
tially generated from a review of the clinical litera-
ture. Several validation studies of treatment bur-
den and quality of life instruments for patients
receiving injectable diabetes therapy were identi-
fied via a Medline keyword search [11–13]. Spe-
cific questions in these instruments were used as
the basis for the ILQ questions. A draft question-
naire was reviewed by a panel of clinical experts
who assessed the instrument’s content and face va-
lidity. In addition, the experts suggested specific
aspects of acromegaly therapy assumed to be cor-
related with treatment burden.
In addition to 24 specific questions originally
conceived to map to the model domains of bur-
den, disruption, and compliance, 6 additional ques-
tions were included: an overall quality of life ques-
tion, satisfaction with therapy, patients’ beliefs about
the impact of therapy on their health (2 questions),
their perception of how worthwhile treatment is,
and a question about the difficulty of obtaining re-
fills. Global quality of life, satisfaction, and conve-
nience questions were scored on a 7-point Likert
scale. The quality of life question was scored 1 
 

 
Very Poor to 7 
 

 
 Excellent, while satisfaction was
scored 1 
 

 
 Very Dissatisfied to 7 
 

 
 Very Satisfied
and convenience was scored 1 
 

 
 Very Inconve-
nient to 7 
 

 
 Very Convenient (the convenience
question was intended to be part of the Burden
subscale). The remaining questions were measured
on a 5-point scale from 1 
 

 
 Strongly Disagree to
5 
 

 
 Strongly Agree.
 
SF-12.
 
The SF-12 was included as a generic mea-
sure of health status, and it was included in the
ILQ to allow for comparisons of study popula-
tions against US norms, and as a measure of con-
current validity. This instrument is a frequently
used measure and consists of 12 items from which
a physical and mental health summary score are
derived. The scoring algorithm involves reverse
scoring several items so that a higher score indi-
cates a better health status, creating and weighting
indicator variables for each response option using
 
regression weights derived from studies in the US
population, then adding an intercept term. This
procedure results in T scores (mean 
 

 
 50, SD 
 

 
10) that can be statistically compared to the US
population.
 
Beck Depression Inventory.
 
The Beck Depres-
sion Inventory is a widely used self-report measure
of depressive symptoms [14]. Each symptom is
scored on a 4-point scale from 0 to 3; 0 indicates
that the patient does not feel a particular symptom
and 3 indicates that the patient feels a particular
symptom very severely. The final score is the sum
of the symptoms. A score of 16 or greater is con-
sidered potentially indicative of major depression.
 
Acromegaly Symptom Distress.
 
We included a list
of 21 common clinical symptomatic features of ac-
romegaly derived from a medical text and reviewed
by a specialist physician coauthor (LK). These
symptoms were measured on a 5-point scale rang-
ing from 0 
 

 
 “I do not have this symptom” to 5 
 

 
“I have this symptom and it bothers me terribly.”
 
Self-Care Burden Scale.
 
The Self-Care Burden Scale
is a measure of the burden of treatment based on
Orem’s theory of self-care [15]. There are 8 items
measuring health deviation (referring to specific
activities required to follow a treatment plan such
as following a special diet or receiving medical/
nursing treatments) and 8 items measuring univer-
sal self-care (effects of treatment and illness on se-
lected aspects of daily living such as personal care
or household tasks). Each health deviation item is
rated twice, once on a 5-point demand scale from
1 
 

 
 None to 5 
 

 
 A Great Deal and once on a 5-
point difficulty scale with the same response op-
tions. 
 
Demand
 
 refers to the extent to which the
treatment plan requires a particular activity, and
 
difficulty
 
 refers to how difficult or bothersome an
activity is to perform. Demand and difficulty are
multiplied to obtain a burden index. Universal
self-care items are also rated twice, once on a 5-point
change scale and once on a 5-point difficulty scale,
using the same response options as for the health
deviation scales. 
 
Change
 
 refers to the extent to
which illness or treatment has changed the pa-
tient’s ability to accomplish certain activities such
as personal care, and 
 
difficulty
 
 refers to how diffi-
cult or bothersome the activity is to perform. The
scale has been used in a study of cancer patients
receiving radiation to examine the impact of self-
care burden, appraisal of illness, and symptom
distress on mood [15], and in a descriptive study
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of self-care burden in women with human immun-
odeficiency virus [16].
 
Appraisal of Illness Scale.
 
The Appraisal of Ill-
ness Scale is a measure of the perceived stress asso-
ciated with illness. It consists of 27 stress items
plus 5 benign items that are unscored. The latter
items are included to avoid creating an overly neg-
ative response set in respondents. Several items re-
lated to general stressfulness are reverse scored.
The scale is rated on a 5-point scale from 1 
 

 
 Very
False (does not have the perception) to 5 
 

 
 Very
True. Only the total score, derived by summing
the responses, is used, unless there are sufficient
data to test the factor structure of hypothesized sub-
scales (Marilyn Oberst, personal communication).
 
Open-Ended Question.
 
At the end of the survey,
patients were asked to “further describe their ex-
perience with acromegaly and its treatment, espe-
cially focusing on areas you feel our question-
naires might have missed.”
 
Data Analysis
 
All data were entered twice and the resulting data-
bases were compared using the COMPARE proce-
dure in SAS (SAS Institute, Cary, NC), with dis-
crepant observations checked against the original
surveys. Descriptive statistics were computed on
all variables to ensure that values were valid. Scales
were scored as described above under each scale.
Factor analysis was conducted with the inclusion
of an additional 56 subjects from a separate study,
as described above. To ensure the comparability
of the two samples, they were compared on avail-
able demographic variables, selected disease-related
variables, and the distribution of their responses
to the items on the questionnaire. In addition, the
factor analysis was initially performed separately
in both samples. The factor analysis performed in-
volved the extraction of principal components
with orthogonal varimax rotation. Three-, four-,
and five-factor solutions were examined in order
to determine how well the measurement model
was supported by factor analysis, although no for-
mal tests of goodness-of-fit were performed. Only
factors with an eigenvalue 
 

 
1 were rotated. The
factor analysis results were examined according to
how well they conformed to the original conceptu-
alization of the factor structure. In addition, items
were retained in a factor if they had a loading of
greater than 0.45, and did not have a loading of
0.45 or greater on any other factor. Reliability was
examined using Cronbach’s 
 

 
 [17]. Test-retest re-
liability was calculated using intraclass correlation
coefficients on each of the ILQ subscales. Pearson
correlations were computed between all scales to
test the size of the associations between them.
To examine the possible confounding effects of
depression on impact on lifestyle, we calculated
semipartial correlation coefficients for several three
variable models, which indicated the amount of
variance independently accounted for after con-
trolling for depression. More extensive multivari-
ate modeling was not feasible given the small sam-
ple size.
 
Results
 
Patient Characteristics
 
The mean age of the 34 survey respondents was
44.4 (SD 
 

 
 13.1). Table 1 indicates that the sur-
vey sample was mostly white, female, employed,
and married, with all but 11.8% having at least
some college education. The average duration since
the diagnosis of acromegaly was 7.3 years (SD 
 

 
5.9). Of the 34 respondents, 85.3% had received
surgical treatment, 76.5% had received radiation
 
Table 1
 
Demographic characteristics of study samples
 
Survey
sample (%)
(n 
 

 
 34)
Factor analysis
sample (%)
(n 
 

 
 56)
Male 38.2 48.2
Female 61.8 44.6
Missing 7.1
Race
White 88.2 76.8
African American 5.9 7.1
Asian 2.9 7.1
Other 2.9 3.6
Missing 5.4
Education
High school/GED 11.8
Some college 29.4
College degree 11.8
Some post college 14.7
Graduate/professional degree 32.4
Student
Full-time 8.8
Part-time 5.9
Not a student 85.3
Employment
Full-time 50.0
Unemployed 11.8
Part-time 20.6
Other 17.6
Marital Status
Married 82.4
Divorced 5.9
Never married 11.8
 
Note.
 
 Demographic information other than sex and race not available for fac-
tor analysis sample.
 Validating the ILQ
 
265
 
therapy, and 70.6% had received both modalities.
Only 8.8% had received neither. Five (14.7%) of
the patients had given themselves injectable medi-
cations for conditions other than acromegaly.
These conditions were not specified but two of the
patients had diabetes and one had a migraine di-
agnosis, which were the most plausible comorbid-
ities requiring medication self-injection.
Six of the 34 patients reported having taken oc-
treotide intermittently. Among the remaining 82.4%
of patients who had taken octreotide continu-
ously, the average duration of octreotide therapy
was 5.2 years (SD 
 

 
 3.8). Many patients (50%)
reported having received other medications in-
cluding bromocriptine, prednisone, sertraline, hy-
drocortisone, hydrochlorothiazide, testosterone, va-
sopressin, and levothyroxine. Finally, 52.9% had
comorbid conditions, including 20.6% with mi-
graine, 17.6% with arthritis, 14.7% with cancer,
11.8% with sleep apnea, 5.9% with diabetes, and
2.9% with coronary artery disease or congestive
heart failure.
There were 56 patients whose baseline data on
the ILQ were used for the factor analysis. Their
average age was 45.9 years (SD 
 

 
 16.2). Table 1
indicates that there was a higher percentage of
males and minorities in the factor analysis sample
than in the survey sample. In this group, 71.4%
had received pituitary surgery, but this proportion
was not significantly different from that reported
in the survey sample (
 

 
2
 
(1) 
 

 
 2.25, n.s.). The av-
erage time since diagnosis of acromegaly was 7.6
years (SD 
 

 
 7.01), while the duration of treatment
with octreotide subcutaneous was 5.7 years (SD 
 

 
3.7). Neither of these values was significantly dif-
ferent from the survey sample. We examined the
ILQ item means and standard deviations, compar-
ing them at baseline using 
 
t
 
 tests. Only four means
were significantly different across the two samples.
Thus, although there were some demographic dif-
ferences across the samples, age, time since diag-
nosis, frequency of surgery, and most important,
length of time on treatment were similar.
 
Factor Analysis and Reliability
 
In both samples, five significant components were
extracted, accounting for 75.4% of the variance in
the survey sample and 70.0% in the clinical trial
sample. These results, and the other similarities
across the groups, suggested that pooling the sam-
ples was legitimate. The three-factor solution in
the pooled sample was the most readily interpret-
able and conformed most closely to the hypothe-
sized factor structure of the scale. The three fac-
tors accounted for 57.1% of the variance, with the
first factor accounting for 39% of the variance,
the second factor accounting for 10.8%, and the
third factor accounting for 7.4% (extraction sums
of squared loadings). Table 2 presents the rotated
factor loadings for the three-factor solution in the
23 items scored on the 5-point Likert scale and
conceived as part of the ILQ. Cross-loading items
were removed from subsequent analyses. Every re-
maining item loaded significantly onto the domain
to which it was hypothesized to belong. These do-
mains were Compliance, Burden, and Impact on
Lifestyle. The Cronbach’s 
 

 
 for Compliance 
 

 
0.86, for Burden 
 

 
 
 

 
 0.82, and for Disruption 
 

 
 
 

 
0.89, indicating that all three subscales showed
good internal consistency. Fourteen patients com-
pleted the scales at two intervals: the intraclass
correlations for the three subscales, respectively,
were 
 
r
 
 
 

 
 .80, 
 
r
 
 
 

 
 .89, and 
 
r
 
 
 

 
 .89, indicating sta-
bility of responses across time. Item descriptive
statistics for the items retained in the final mea-
sure are presented in Table 3.
 
Validation Analyses
 
Table 4 presents the descriptive results for the
scaled scores. Compliance, Burden, and Disrup-
tion are scored such that higher scores indicate
more noncompliance, more burden, and more dis-
ruption. The internal consistency coefficients (Cron-
bach’s 
 

 
’s) indicate that all the scales are reliable.
The scale scores were well distributed across the
range, in general, with no scale other than the
Compliance scale having more than 9% of obser-
vations at the floor or the ceiling. The Compliance
scale showed a floor effect with 11 subjects (33.3%,
n 
 

 
 33) scoring at the floor (indicating good per-
ceived compliance). Only 8.8% scored at the ceil-
ing for the Burden scale and 2.9% scored the
maximum on the Disruption scale. On the ILQ,
these patients acknowledge only a small amount
of noncompliance with the medication, indicating
on average that they “somewhat disagree” with
statements like “My job caused me to miss doses
of Sandostatin.” They slightly disagree with state-
ments like “I worry about other people getting
hurt by my used needles” (Burden subscale). In
addition, these patients denied on average a nega-
tive disruption to their lives, tending to “some-
what disagree” with statements like “My Sando-
statin therapy interfered with my social life” and
“My Sandostatin therapy has kept me from doing
things I enjoy.”
The scores for the SF-12 indicate that these pa-
tients fall about 1 standard deviation below the
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US norm in terms of mental well-being, and about
0.8 of a standard deviation below in terms of
physical health. This is consistent with both a con-
siderable amount of depressive symptoms reported
and a mild mean level of physical symptoms re-
ported (consistent with the statement “I have this
symptom and it does not bother me”). In fact, us-
ing the Beck cutoff score of 16 or greater, 26.5%
 
Table 2
 
Rotated component matrix of ILQ—factor loadings
 
Component
ILQ item stem (subscale) I II III
1. . . . received all doses I was supposed to* (C)
 

 
.25 .00
 

 
.75
 
2. . . . skipped doses to attend family events (C) .22 .16
 
.84
 
3. . . . skipped doses because they interfered with social activities (C) .20 .26
 
.81
 
4. . . . job caused me to miss doses (C) .20 .20
 
.78
 
5. . . . In the past 4 weeks, . . . missed at least one dose (C) .00 .00
 
.74
 
6. . . . worry about carrying around syringes and needles (B) .34
 
.71
 
.13
7. . . . worry about running out (B) .00
 
.71
 
.00
8. . . . worry about other people getting hurt by used needles (B) .30
 
.68
 
.13
9. . . . refrigeration was sometimes a problem (B) .17
 
.67
 
.14
10. . . . disposal of used needles is sometimes a problem (B) .32
 
.75
 
.00
11. . . . injections cause moderate pain (D)
 
.56
 
.29
 
.19
12. . . . therapy causes me embarrassment† (D) .55 .60 .16
13. . . . therapy interfered with my social life† (D) .72 .48 .00
14. . . . therapy interfered with family life (D) .74 .44 .12
15. . . . therapy did not affect my daily routine* (D) .61 .00 .16
16. . . . therapy caused me to miss or be late for work (D) .52 .00 .16
17. . . . would do a better job at work (D) .70 .00 .15
18. . . . work routine was not affected by therapy* (D) .67 .00 .14
19. . . . therapy had a negative impact on normal daily activities (D) .70 .32 .00
20. . . . missed family events because of therapy (D) .56 .31 .16
21. . . . therapy was disruptive to lifestyle (D) .80 .37 .18
22. . . . hide from others that I need to take therapy† (D) .53 .48 .15
23. . . . therapy has kept me from doing things I enjoy (D) .68 .19 .00
*Item is reverse scored in final instrument. †Item is deleted from final instrument.
Note. Extraction method: principal component analysis. Rotation method: varimax with Kaiser normalization. Bold items indicate which items belong to which sub-
scale. Subscale abbreviations in parentheses.
B, Burden; C, Compliance; D, Disruption.
Table 3 Item descriptive statistics
Item Mean Median Mode SD
Item-total
correlation
. . . received all doses I was supposed to (C)* 1.63 1.00 1.00 1.24 .65
. . . skipped doses to attend family events (C) 2.21 1.00 1.00 1.60 .79
. . . skipped doses because they interfered with social activities (C) 2.27 1.00 1.00 1.66 .80
. . . job caused me to miss doses (C) 2.03 1.00 1.00 1.59 .72
. . . in the past 4 weeks, . . . missed at least one dose (C) 2.91 3.00 1.00 1.93 .58
. . . worry about carrying around syringes and needles (B) 2.59 2.00 1.00 1.67 .69
. . . worry about running out (B) 2.94 3.00 1.00 1.65 .50
. . . worry about other people getting hurt by used needles (B) 2.12 1.00 1.00 1.51 .67
. . . refrigeration was sometimes a problem (B) 3.26 4.00 4.00 1.58 .54
. . . disposal of used needles is sometimes a problem (B) 2.68 2.00 1.00 1.65 .66
. . . injections cause moderate pain (D) 2.91 3.00 4.00 1.48 .50
. . . therapy interfered with family life (D) 2.03 1.00 1.00 1.47 .75
. . . therapy did not affect my daily routine (D)* 3.21 3.00 5.00 1.49 .55
. . . therapy caused me to miss or be late for work (D) 1.42 1.00 1.00 0.90 .47
. . . would do a better job at work (D) 1.73 1.00 1.00 1.10 .62
. . . work routine was not affected by therapy (D)* 4.03 5.00 5.00 1.26 .60
. . . therapy had a negative impact on normal daily activities (D) 2.35 2.00 1.00 1.52 .72
. . . missed family events because of therapy (D) 1.53 1.00 1.00 0.93 .60
. . . therapy was disruptive to lifestyle (D) 2.24 2.00 1.00 1.44 .84
. . . therapy has kept me from doing things I enjoy (D) 1.82 1.00 1.00 1.22 .62
*Items that have been reverse scored.
Note. All items are scored on the scale 1  Strongly Disagree, 2  Somewhat Disagree, 3  Neither Agree nor Disagree, 4  Somewhat Agree, 5  Strongly
Agree. Only items that were retained in the final version of the scale are included in the table.
B, Burden; C, Compliance; D, Disruption to Lifestyle.
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of those completing the scale (n  30) reported
depressive symptoms consistent with major de-
pression. On the Self-Care Burden scale, patients
indicated a small to moderate amount of both de-
mand and difficulty associated with their acrome-
galy treatment, yet only a small amount of change
in their ability to do usual activities as a result of
their illness or treatment, and a small amount of
difficulty associated with performing these activi-
ties.
Table 5 shows the intercorrelations between all
the scales in Table 4, as well as several single-item
measures, thus illustrating the ways the ILQ dem-
onstrated convergent validity. For example, the ILQ
Burden scale is conceptually most similar to the
Self-Care Burden scales and the Burden index, and
in fact it was strongly correlated with them. The
range of correlations (r  .55–.62) suggests these
measures are closely related but not redundant. The
Disruption to Lifestyle subscale was also correlated
with the Self-Care Burden scales (r  .49–.61). The
Burden and Disruption scales showed a strong cor-
relation. The Disruption and Burden scales were
similarly correlated with Depression, Symptoms, and
Appraisal of Illness. However, the Disruption scale
was more highly correlated with the Satisfaction
question than the Burden scale was, while the Bur-
den scale was more highly correlated with the SF-12
Mental Component Score. Of interest, the Burden
scale was not significantly correlated with the Con-
Table 4 Descriptive statistics
Descriptive statistics
N Minimum Maximum Mean SD Cronbach’s 
Symptoms 34 0.00 3.24 1.27 0.72 0.89
Compliance (ILQ) 33 1.00 5.00 2.21 1.29 0.86
Burden (ILQ) 34 1.00 5.00 2.72 1.17 0.82
Disruption (ILQ) 34 1.30 4.30 2.09 0.97 0.89
Beck Depression score 30 0.00 36.00 12.07 8.68 0.90
Self-Care demand 33 1.25 3.75 2.30 0.72 0.83
Self-Care difficulty 33 1.00 3.88 2.17 0.71 0.81
Universal Self-Care change 34 1.00 4.25 2.04 0.86 0.88
Universal Self-Care difficulty 34 1.00 3.63 1.96 0.78 0.86
Self-Care Burden index 33 1.38 14.53 5.40 3.37 *
SF-12 mental component 32 24.44 59.44 40.26 9.92 *
SF-12 physical component 32 20.84 58.29 42.74 9.55 *
Compliance (ILQ) time 2 14 1.00 4.00 2.18 0.91 0.73
Burden (ILQ) time 2 14 1.00 5.00 2.91 1.18 0.80
Disruption (ILQ) time 2 14 1.10 4.50 2.09 1.04 0.93
*Cronbach’s  was not calculated for these previously validated summary measures.
Note. The ILQ scales are scored so that higher scores indicate greater Noncompliance, more Burden, and more Disruption.
ILQ, Impact on Lifestyle Questionnaire.
Table 5 Correlations
COMP BURD DIS SAT QoL
Burden (ILQ) .47** — — — —
Disruption (ILQ) .22 .60** — — —
Satisfaction .41* .14 .57** — —
QoL question .13 .29 .37* .64*** —
Convenience question .47** .26 .58*** .76*** .39*
Beck Depression score .07 .42* .50** .47*** .65***
Self-Care demand .06 .59** .49** .24 .47**
Self-Care difficulty .03 .56*** .56*** .28 .50**
Universal Self-Care change .12 .59*** .59*** .34* .58***
Universal Self-Care difficulty .03 .55*** .61*** .38* .62***
Self-Care Burden index .09 .62*** .51** .21 .47**
SF-12 mental component score .02 .36* .25 .33 .46**
SF-12 physical component score .11 .04 .20 .29 .38*
AOI—overall mean score .003 .52** .50** .41* .66***
Symptoms .06 .59*** .58*** .26* .39*
***P  .001 level (two-tailed); **P  .01 level (two-tailed); *P  .05 level (two-tailed).
Note. n  31–34.
BURD, Burden (ILQ); COMP, Compliance (ILQ); DIS, Disruption (ILQ); ILQ, Impact on Lifestyle Questionnaire; QoL, quality-of-life question; SAT, satisfaction ques-
tion.
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venience question, which suggests that the burdens
associated with therapy were not related to the con-
venience of therapy per se.
Table 5 also shows that the ILQ scale Compli-
ance was moderately negatively correlated with
Satisfaction and Convenience and positively corre-
lated with Disruption, but not significantly corre-
lated with Burden, due to the small sample size.
Compliance was not correlated with Symptoms;
this may be due to the low burden of current
symptoms in this group. Compliance was not cor-
related with any of the measures of quality of life.
Discussion
We constructed a set of questions (the Impact on
Lifestyle Questionnaire or ILQ) to assess the im-
pact of injectable therapies for acromegaly on pa-
tient’s lifestyles. The results of our field test pro-
vide preliminary evidence that the ILQ is reliable
and demonstrates construct validity. Establishing
validity requires demonstrating reliability, which
this study has effectively achieved. Evidence for
the reliability of the subscales of the ILQ was pro-
vided by the high internal consistency of the scales
and their stability over time. The scales were formed
based on a conceptualization of the impact of ac-
romegaly treatments on lifestyle; the item set was
subjected to a factor analysis. The three-factor so-
lution in the factor analysis corresponded closely
to our expectations about what the factors were
measuring, and it accounted for 57% of the vari-
ance in the measure.
Validity also requires that there be evidence that
the scale is measuring what it purports to measure.
We sought to establish validity through the concur-
rent administration of measures of both related and
divergent concepts. The ILQ Burden scale in fact
showed strong correlations with a previously vali-
dated measure of treatment burden, the Self-Care
Burden scale [16,17]. Disruption to Lifestyle was
negatively correlated with Treatment Satisfaction,
and showed a trend on Quality of Life, while it was
positively correlated with Depression, Symptoms,
and stressful Appraisal of Illness. Our relatively
small sample size did not allow us to formally test
the multivariate relationships among these vari-
ables, or to test a formal model of impact on life-
style. However, we did examine the extent to which
various aspects of impact on lifestyle were related
to each other while controlling for depression.
These analyses indicated that there was consider-
able variance shared between Disruption, Burden,
and Compliance (semipartial correlation, or sr2 
.12–.35) which was independent of depression, al-
though these results were not statistically signifi-
cant, most likely due to small sample size.
This sample of patients with acromegaly had
significantly impaired mental well-being and phys-
ical functioning when compared with nationwide
norms, scoring approximately 1 standard devia-
tion below the general population in the mental
domain and 0.8 below the population in physical
functioning. The impairment in well-being was re-
flected in high mean scores for depression. How-
ever, the respondents reported only mild levels of
current symptoms. Whether this poor well-being
is the result of the disease, treatments, comorbid ill-
nesses, or other unmeasured patient characteristics
cannot be ascertained from our study. The 82% of
patients who had been taking octreotide continu-
ously since initiation of the therapy had been tak-
ing it for an average of 5.2 years. Accordingly, we
may assume that this sample of clinic patients,
given the presence of other treatment options, re-
mained on octreotide subcutaneous either because
their disease was reasonably well controlled, the
side effects associated with the therapy were not
intolerable, and/or the therapy was not overly bur-
densome. We must consider these characteristics of
the patients in interpreting the results of the ILQ
observed in this study.
In terms of impact on lifestyle, these patients
disagreed that they had difficulty complying with
their medication, and they disagreed on the whole
that their treatment is a burden or that their treat-
ment caused a disruption to their lifestyle. These
findings were consistent with the results on the
Self-Care Burden scale, in which patients on the
whole indicated only a small amount of demand
and difficulty associated with their treatment plan.
This might seem counterintuitive when describing
a treatment regimen requiring multiple daily self-
injections. However, there are several possible ex-
planations for these findings: the medication regi-
men is truly not overly disruptive or burdensome;
over time, patients may adapt to the burdens of
treatment so that their lifestyle is not affected, or
they may modify their lifestyle so as to conform to
the demands of treatment. Alternatively, patients
may be denying the true impact of the treatment as
a method of coping. Finally, patients may weigh
the burden and disruption of treatment against the
benefits of disease control and find that the value
of the latter outweighs the former, and adjust their
evaluations accordingly. Our data do not permit us
to answer whether the low levels of burden and
disruption reported reflect adaptation or denial.
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Patients provided open-ended comments regard-
ing aspects of their disease and treatment. Most of
the comments were not directly relevant to the
content of the ILQ, for example, describing other
comorbidities, psychological issues, and the effects
of the disease. However, the comments that were
targeted toward the constructs measured in the
questionnaire were consistent with the results re-
ported. Overall, the reaction to the medication
regimen was mixed. With respect to compliance,
issues like the need for refrigeration and the way
the shots interfered with meals were important.
For example, one subject said, “The shots inter-
fere with my eating schedule such that I now skip
the middle shot each day.” Another individual re-
ported, “Injections can be a nuisance, particularly
at work when I am very busy, otherwise not a big
deal.” On the other hand, one individual said,
“The . . . injections are pretty simple.” Another in-
dividual said, “[Medication] has controlled GH &
IGF-1 very well; needles are only a minor inconve-
nience.” These statements are consistent with the
mild levels of noncompliance, burden, and disrup-
tion reported via the structured questionnaire.
In summary, the results of this field test of the
ILQ indicate that it consists of three subscales:
Compliance, Burden, and Disruption to Lifestyle.
These scales are reliable, and show preliminary ev-
idence of construct validity. Although many of the
variables in the study were only measured in a
small survey sample, the factor analysis was con-
ducted on a pooled sample. This increased sample
size for the factor analysis, although still less than
ideal, increases our confidence in the results. Fur-
ther research could be done with the scale. First, it
would be useful to establish its applicability in pa-
tients using other injectable treatments for ac-
romegaly. In addition, we did not examine changes
over time as the result of changes in treatment.
Further research is required to demonstrate the re-
sponsiveness of the scale to treatment effects.
Source of funding: Novartis Pharmaceuticals Corpora-
tion. We wish to thank Dr. Marilyn Oberst for the use of
her questionnaires in the study.
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